Determination of Parkinson Disease Laterality After Deep Brain Stimulation Using 123I FP-CIT SPECT.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
pubmed:
29
2
2020
medline:
7
7
2020
entrez:
29
2
2020
Statut:
ppublish
Résumé
Symptom laterality is one of the main characteristics of Parkinson disease (PD) and reported to be associated with motor and nonmotor symptom severity and prognosis. This study aimed to evaluate the changes of laterality after deep brain stimulation (DBS) and the association between dopamine transporter SPECT using I FP-CIT (DAT SPECT) and symptom laterality in PD before and after DBS. Nineteen patients with PD who received bilateral subthalamic nucleus DBS were enrolled. The clinical scores including Unified Parkinson Disease Rating Scale (UPDRS) and Hoehn and Yahr were evaluated at baseline, 6 months, and 1 year after DBS. Also, the patients underwent DAT SPECT before and 6 months and 1 year after DBS. Symptom and DAT laterality indices were determined based on the UPDRS part 3 and DAT SPECT, respectively. The association between DAT and symptom laterality was assessed at baseline and 6 months and 1 year after DBS. At baseline, 11, 6, and 2 among 19 patients had left-side-dominant, right-side-dominant, and symmetric motor symptom, respectively. Among 19 patients, there were 10 patients who showed changed symptom laterality within 1 year after DBS. The agreement between symptom laterality and DAT laterality was good to excellent at baseline and 6 months and 1 year after DBS (weighted κ = 0.742, 0.736, and 0.813). Furthermore, symptom and DAT laterality indices showed significant correlation at baseline (r = 0.542, P = 0.02), 6 months (r = 0.579, P = 0.01), and 1 year after DBS (r = 0.689, P = 0.02). Symptom laterality could be determined by DAT laterality index with areas under curve of 0.833 (P = 0.045), 0.982 (P < 0.001), and 1.000 (P < 0.001) at baseline and 6 and 12 months after DBS, respectively. The symptom laterality could be altered after DBS and was well correlated with laterality evaluated by DAT SPECT. An objective evaluation of laterality using DAT SPECT would be helpful for the management of patients with PD especially for adjusting the DBS programming for fine balancing of the asymmetric symptom after DBS. The large-scale study is warranted for validation of this result.
Identifiants
pubmed: 32108695
doi: 10.1097/RLU.0000000000002955
pii: 00003072-202004000-00023
doi:
Substances chimiques
Radiopharmaceuticals
0
Tropanes
0
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane
155797-99-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e178-e184Références
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386:896–912.
Starkstein S, Leiguarda R, Gershanik O, et al. Neuropsychological disturbances in hemiparkinson's disease. Neurology. 1987;37:1762–1764.
Katzen HL, Levin BE, Weiner W. Side and type of motor symptom influence cognition in Parkinson's disease. Mov Disord. 2006;21:1947–1953.
Baumann CR, Held U, Valko PO, et al. Body side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression. Mov Disord. 2014;29:207–213.
Spicer KB, Roberts RJ, LeWitt PA. Neuropsychological performance in lateralized parkinsonism. Arch Neurol. 1988;45:429–432.
Scherfler C, Seppi K, Mair KJ, et al. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. Brain. 2012;135:3348–3354.
Wang J, Yang QX, Sun X, et al. MRI evaluation of asymmetry of nigrostriatal damage in the early stage of early-onset Parkinson's disease. Parkinsonism Relat Disord. 2015;21:590–596.
Heinrichs-Graham E, Santamaria PM, Gendelman HE, et al. The cortical signature of symptom laterality in Parkinson's disease. NeuroImage Clin. 2017;14:433–440.
Spiegel EA, Wycis HT, Marks M, et al. Stereotaxic apparatus for operations on the human brain. Science. 1947;106:349–350.
Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355:896–908.
Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368:610–622.
Hacker ML, DeLong MR, Turchan M, et al. Effects of deep brain stimulation on rest tremor progression in early stage. Parkinson Dis. 2018;91:e463–e471.
Lizarraga KJ, Luca CC, De Salles A, et al. Asymmetric neuromodulation of motor circuits in Parkinson's disease: the role of subthalamic deep brain stimulation. Surg Neurol Int. 2017;8:261.
Duffus S, Chukwueke U, Strowd R, et al. Unilateral vs. bilateral subthalamic stimulation in Parkinson's disease. Neurology. 2015;84(14 Suppl):P1.168.
Taba HA, Wu SS, Foote KD, et al. A closer look at unilateral versus bilateral deep brain stimulation: results of the National Institutes of Health COMPARE cohort. J Neurosurg. 2010;113:1224–1229.
Ehm G, Kim HJ, Kim JY, et al. Effect of unilateral subthalamic deep brain stimulation in highly asymmetrical Parkinson's disease: 7-year follow-up. J Neurosurg. 2018;1–6.
Picillo M, Lozano AM, Kou N, et al. Programming deep brain stimulation for Parkinson's disease: the Toronto Western Hospital algorithms. Brain Stimul. 2016;9:425–437.
Volkmann J, Moro E, Pahwa R. Basic algorithms for the programming of deep brain stimulation in Parkinson's disease. Mov Disord. 2006;21(suppl 14):S284–S289.
Paek SH, Kim HJ, Yoon JY, et al. Fusion image-based programming after subthalamic nucleus deep brain stimulation. World Neurosurg. 2011;75:517–524.
Kim H-J, Jeon BS, Paek SH, et al. Bilateral subthalamic deep brain stimulation in Parkinson disease patients with severe tremor. Neurosurgery. 2010;67:626–632.
Lee JY, Han JH, Kim HJ, et al. STN DBS of advanced Parkinson's disease experienced in a specialized monitoring unit with a prospective protocol. J Korean Neurosurg Soc. 2008;44:26–35.
Lee JS, Lee DS, Kim YK. Quantification of brain images using Korean standard templates and structural and cytoarchitectonic probabilistic maps. Korean J Nucl Med. 2004;38:241–252.
Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–450.
Joutsa J, Johansson J, Kaasinen V. Is occipital cortex a valid reference region in 123I-FP-CIT SPECT imaging? Clin Nucl Med. 2015;40:615–616.
Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord. 2010;25:578–586.
Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson's disease. Lancet Neurol. 2006;5:796–802.
Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2006;66:968–975.
Thenganatt MA, Louis ED. Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. Expert Rev Neurother. 2012;12:687–696.
Cubo E, Martin PM, Martin-Gonzalez JA, et al. Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. Mov Disord. 2010;25:70–75.
Frazzitta G, Ferrazzoli D, Maestri R, et al. Differences in muscle strength in parkinsonian patients affected on the right and left side. PLoS One. 2015;10:e0121251.
Munhoz RP, Espay AJ, Morgante F, et al. Long-duration Parkinson's disease: role of lateralization of motor features. Parkinsonism Relat Disord. 2013;19:77–80.
Yoon JE, Kim JS, Seo JY, et al. The association between motor laterality and cognitive impairment in Parkinson's disease. Dement Neurocogn Disord. 2016;15:142–146.
Hickey P, Stacy M. Deep brain stimulation: a paradigm shifting approach to treat Parkinson's disease. Front Neurosci. 2016;10:173.
Sung C, Lee JH, Oh JS, et al. Longitudinal decline of striatal subregional [(18)F]FP-CIT uptake in Parkinson's disease. Nucl Med Mol Imaging. 2017;51:304–313.
Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003;18:1415–1423.
Ravina B, Marek K, Eberly S, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord. 2012;27:1392–1397.
Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424–438.
Schillaci O, Pierantozzi M, Filippi L, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with (123)I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005;32:1452–1456.
Meissner W, Leblois A, Hansel D, et al. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain. 2005;128:2372–2382.
Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci. 1996;8:1408–1414.
Temel Y, Visser-Vandewalle V, Kaplan S, et al. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res. 2006;1120:100–105.
Lokkegaard A, Werdelin LM, Regeur L, et al. Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging. 2007;34:508–516.